PLK1 and recessive dystrophic epidermolysis bullosa: Additional targeted or immune-modulating agents (e.g., PLK1 inhibition with rigosertib in RDEB-associated aCSCC) illustrate the heterogeneity of advanced disease and the need for tailored trials in genetically or clinically defined subsets [78].